# A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion

> **NCT07649369** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Jeyou Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Malignant Pleural Effusions (Mpe)

## Interventions

- **DRUG:** JMKX000197
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07649369
- **Lead sponsor:** Shanghai Jeyou Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-17
- **Primary completion:** 2028-01-12
- **Final completion:** 2028-08-14
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07649369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07649369, "A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07649369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*